[go: up one dir, main page]

NO20015546L - Behandling av refrakt¶re humane tumorer med epidermale vekstfaktorreseptorantagonister - Google Patents

Behandling av refrakt¶re humane tumorer med epidermale vekstfaktorreseptorantagonister

Info

Publication number
NO20015546L
NO20015546L NO20015546A NO20015546A NO20015546L NO 20015546 L NO20015546 L NO 20015546L NO 20015546 A NO20015546 A NO 20015546A NO 20015546 A NO20015546 A NO 20015546A NO 20015546 L NO20015546 L NO 20015546L
Authority
NO
Norway
Prior art keywords
treatment
growth factor
receptor antagonists
factor receptor
epidermal growth
Prior art date
Application number
NO20015546A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015546D0 (no
Inventor
Harlan W Waksal
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26978320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20015546(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of NO20015546D0 publication Critical patent/NO20015546D0/no
Publication of NO20015546L publication Critical patent/NO20015546L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20015546A 1999-05-14 2001-11-13 Behandling av refrakt¶re humane tumorer med epidermale vekstfaktorreseptorantagonister NO20015546L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31228499A 1999-05-14 1999-05-14
US37402899A 1999-08-13 1999-08-13
PCT/US2000/011756 WO2000069459A1 (fr) 1999-05-14 2000-05-01 Traitement de tumeurs humaines refractaires avec des antagonistes de recepteurs du facteur de croissance epidermique

Publications (2)

Publication Number Publication Date
NO20015546D0 NO20015546D0 (no) 2001-11-13
NO20015546L true NO20015546L (no) 2002-01-14

Family

ID=26978320

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015546A NO20015546L (no) 1999-05-14 2001-11-13 Behandling av refrakt¶re humane tumorer med epidermale vekstfaktorreseptorantagonister

Country Status (20)

Country Link
US (3) US20020012663A1 (fr)
EP (2) EP1218032A4 (fr)
JP (2) JP2003520195A (fr)
KR (1) KR20020000223A (fr)
CN (1) CN1200734C (fr)
AU (1) AU782994C (fr)
BG (1) BG106110A (fr)
BR (1) BR0010524A (fr)
CA (1) CA2373815A1 (fr)
CZ (1) CZ20014083A3 (fr)
EE (1) EE200100603A (fr)
HK (1) HK1047236A1 (fr)
HU (1) HUP0201480A3 (fr)
IL (1) IL146480A0 (fr)
MX (1) MXPA01011632A (fr)
NO (1) NO20015546L (fr)
PL (1) PL365999A1 (fr)
RU (1) RU2294761C2 (fr)
SK (1) SK16522001A3 (fr)
WO (1) WO2000069459A1 (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
HUP0201480A3 (en) * 1999-05-14 2009-03-30 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
AU2001295002B2 (en) * 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
EP1236474A1 (fr) * 2001-02-26 2002-09-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Regulation négative du récepteur de l'EGF par Mig-6
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
WO2002100326A2 (fr) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies permettant de traiter un cancer a l'aide d'immunoconjugues de photosensibilisant et de therapies de combinaison
MXPA03010121A (es) * 2001-05-08 2004-03-10 Merck Patent Gmbh Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
EP1392359B2 (fr) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Proteines de liaison specifiques et utilisations associees
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
KR100719624B1 (ko) * 2001-05-18 2007-05-21 석정철 시각장애인을 위한 접착형 점자유도블록 및점자유도블록의 접착방법
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003002609A2 (fr) * 2001-06-28 2003-01-09 Domantis Limited Ligand
EP1478358B1 (fr) 2002-02-11 2013-07-03 Bayer HealthCare LLC Tosylate de sorafenib pour le traitement des maladies caractérisées par une angiogénèse anormale
WO2003075947A1 (fr) * 2002-03-08 2003-09-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Utilisation d'inhibiteurs de la transactivation de l'egfr dans le traitement du cancer humain
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
JP2006523090A (ja) * 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
WO2004060400A1 (fr) * 2003-01-06 2004-07-22 Mitsubishi Pharma Corp Recepteur antipsychotique du facteur de croissance epitheliale a ciblage moleculaire
WO2004073601A2 (fr) * 2003-02-21 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Nouveau procede de preparation de composes hexacycliques
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
ES2288694T3 (es) 2003-05-20 2008-01-16 Bayer Pharmaceuticals Corporation Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas.
BRPI0411250A (pt) 2003-06-09 2006-08-29 Samuel Waksal método de inibição de receptor tirosina cinase com um antagonista extracelular e um antagonista intracellular
EP1493445A1 (fr) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition de l'activation de l'EGFR, cette activation étant dépendante d'un ligand et étant induite par le stress
KR101139557B1 (ko) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
CA2540133A1 (fr) * 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. Medicaments pour le traitement du cancer
WO2005037836A2 (fr) * 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazopyrazines utilisees comme inhibiteurs de la tyrosine kinase
PT1735348E (pt) * 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
CN102924458B (zh) 2004-04-02 2014-11-05 Osi制药有限责任公司 6,6-双环取代的杂双环蛋白激酶抑制剂
BRPI0509732A (pt) 2004-04-09 2007-09-25 Chugai Pharmaceutical Co Ltd pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco
CA2567836A1 (fr) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Traitement a base de gemcitabine et d'un inhibiteur de egfr
CN1968706A (zh) * 2004-06-03 2007-05-23 霍夫曼-拉罗奇有限公司 用顺铂和egfr－抑制剂治疗
AU2005249201A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with irinotecan (CPT-11) and an EGFR-inhibitor
JP2008501650A (ja) * 2004-06-03 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー オキサリプラチンおよびｅｇｆｒ阻害剤を用いた処置
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
US20060084691A1 (en) * 2004-10-18 2006-04-20 Bilal Piperdi Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
US20060084675A1 (en) * 2004-10-18 2006-04-20 Thomas Efferth Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor
US20070099856A1 (en) * 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
KR20080066039A (ko) * 2005-10-19 2008-07-15 추가이 세이야쿠 가부시키가이샤 신규 수용성 프로드러그를 함유하는 췌장암, 난소암 또는 간암의 예방 또는 치료제
WO2007049361A1 (fr) * 2005-10-27 2007-05-03 Stelic Corp. Inhibiteur de fibrose hepatique
JP2009519011A (ja) * 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
KR100723641B1 (ko) * 2006-06-07 2007-06-04 실버레이 주식회사 다중 조리가 가능한 솥
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
WO2008046107A2 (fr) * 2006-10-13 2008-04-17 The Regents Of The University Of California Nouveaux inhibiteurs de kinase egfr ciblant l'interface de dimère à activation asymétrique
ES2609094T3 (es) * 2007-01-25 2017-04-18 Dana-Farber Cancer Institute, Inc. Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
JP5618549B2 (ja) * 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
CA2683801A1 (fr) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, domaines variables d'anticorps et antagonistes
MX2010001757A (es) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
US20100323957A1 (en) * 2007-11-19 2010-12-23 The Regents Of The University Of California The Office Of The President Novel assay for inhibitors of egfr
US20110046144A1 (en) * 2008-01-18 2011-02-24 Mulvihill Mark J Imidazopyrazinol derivatives for the treatment of cancers
BRPI0908049A2 (pt) * 2008-03-05 2015-08-11 Novartis Ag Uso de derivados de pririmidina para o tratamento de doenças dependentes de egfr ou de doenças que possuem resistência adquirida a agentes que são direcionados aos membros da família de egfr
EP2283020B8 (fr) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Imidazopyrazines et imidazotriazines substituées
JP2012520893A (ja) 2009-03-18 2012-09-10 オーエスアイ・ファーマシューティカルズ，エルエルシー Ｅｇｆｒ阻害薬及びｉｇｆ−１ｒ阻害剤の投与を含む組み合わせ癌治療
AU2010226453B2 (en) 2009-03-20 2013-11-21 Genentech, Inc. Bispecific anti-HER antibodies
BRPI1016245A2 (pt) 2009-04-20 2015-09-01 Osi Pharmaceuticals Llc Preparação de c-pirazina-metilaminas.
EP2427192A1 (fr) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Utilisation d'osi-906 dans le traitement du carcinome adrénocortical
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
CN103037865B (zh) 2010-05-14 2014-10-29 达那-法伯癌症研究所 用于治疗瘤形成、炎性疾病和其他失调的化合物
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
RU2457546C1 (ru) * 2011-03-09 2012-07-27 Учреждение Российской академии медицинских наук Научный центр реконструктивной и восстановительной хирургии Сибирского отделения РАМН (НЦРВХ СО РАМН) Способ моделирования аденокарциномы толстой кишки человека
WO2012129145A1 (fr) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Polythérapie du cancer du poumon non à petites cellules (nsclc)
JP6088488B2 (ja) 2011-04-21 2017-03-01 シアトル ジェネティックス， インコーポレイテッド 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用
RU2614254C2 (ru) 2011-08-31 2017-03-24 Дженентек, Инк. Диагностические маркеры
KR20140066783A (ko) 2011-09-30 2014-06-02 제넨테크, 인크. 종양 또는 종양 세포에서의 상피 또는 중간엽 표현형 및 egfr 키나제 억제제에 대한 반응의 진단 메틸화 마커
CA2929652A1 (fr) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Polytherapie pour le traitement du cancer utilisant des inhibiteurs de proteine a bromodomaine et a domaine extra-terminal (bet)
MX377534B (es) 2014-02-28 2025-03-10 Tensha Therapeutics Inc Compuestos para usarse en el tratamiento de hiperinsulinemia.
KR20160137599A (ko) 2014-03-24 2016-11-30 제넨테크, 인크. C-met 길항제로의 암 치료 및 이것과 hgf 발현과의 상관관계
CN116333130A (zh) 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
US11912775B2 (en) * 2017-07-18 2024-02-27 Kyowa Kirin Co., Ltd. Anti-human CCR1 monoclonal antibody
EA202092410A1 (ru) * 2018-04-06 2021-02-09 Сиэтл Дженетикс, Инк. Конъюгаты камптотецина с пептидом
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
NL7802170A (nl) * 1977-04-18 1978-10-20 Hitachi Metals Ltd Sierraad.
US4510924A (en) * 1980-07-10 1985-04-16 Yale-New Haven Hospital, Inc. Brachytherapy devices and methods employing americium-241
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5866363A (en) * 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
CA1275922C (fr) * 1985-11-28 1990-11-06 Harunobu Amagase Traitement du cancer
US4846782A (en) 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4763642A (en) * 1986-04-07 1988-08-16 Horowitz Bruce S Intracavitational brachytherapy
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5470571A (en) * 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
DE68921364T2 (de) 1988-04-16 1995-06-29 Celltech Ltd Verfahren zur Herstellung von Proteinen mittels rekombinanter DNA.
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
HU215581B (hu) * 1989-07-06 1999-01-28 Regents Of The University Of California Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5196446A (en) * 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
ATE247168T1 (de) * 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5885793A (en) * 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
AU690528B2 (en) * 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5855885A (en) * 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5550114A (en) * 1993-04-02 1996-08-27 Thomas Jefferson University Epidermal growth factor inhibitor
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5736534A (en) * 1994-02-23 1998-04-07 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
AU2096895A (en) * 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
AU2071695A (en) * 1994-03-17 1995-10-03 Merck Patent Gmbh Anti-EGFR single-chain FVS and anti-EGFR antibodies
US5656655A (en) 1994-03-17 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase
US5869465A (en) * 1994-04-08 1999-02-09 Receptagen Corporation Methods of receptor modulation and uses therefor
US5468754A (en) 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5604233A (en) 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5663144A (en) * 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
JPH11507535A (ja) * 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
AU1441497A (en) * 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
WO1997046684A1 (fr) * 1996-06-06 1997-12-11 University Of Massachusetts Proteines complexes se liant a des recepteurs non actives
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US20030105057A1 (en) * 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US5914269A (en) * 1997-04-04 1999-06-22 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of epidermal growth factor receptor expression
US20020173629A1 (en) * 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
HUP0201480A3 (en) * 1999-05-14 2009-03-30 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
TR200200472T2 (tr) * 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
US6699473B2 (en) * 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
US20020076408A1 (en) * 2000-12-08 2002-06-20 Buchsbaum Donald J. Combination radiation therapy and chemotherapy in conjunction with administration of growth factor receptor antibody
WO2002087618A1 (fr) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
CN100497389C (zh) * 2001-06-13 2009-06-10 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
WO2003075947A1 (fr) * 2002-03-08 2003-09-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Utilisation d'inhibiteurs de la transactivation de l'egfr dans le traitement du cancer humain
US20060264353A1 (en) * 2002-03-21 2006-11-23 Maxey Kirk M Prostaglandin f2alpha analogs and their use in combination with antimicrobial proteins for the treatment of glaucoma and intraocular hypertension
US20050148607A1 (en) * 2002-06-03 2005-07-07 Tsuyoshi Suzuki Preventives and/or remedies for subjects with the expression or activation of her2 and/or egfr
CN1703243B (zh) * 2002-10-10 2011-05-04 默克专利有限公司 针对erb-b1受体的药物组合物
EP1493445A1 (fr) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition de l'activation de l'EGFR, cette activation étant dépendante d'un ligand et étant induite par le stress
EP1687338B1 (fr) * 2003-11-07 2010-10-20 Ablynx N.V. Anticorps a domaine unique vhh de camelidae diriges contre le recepteur de facteur de croissance epidermique et utilisations de ceux-ci
DE10355904A1 (de) * 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
JP2007522157A (ja) * 2004-02-12 2007-08-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗ｅｇｆｒ抗体の高濃縮液体製剤
TW200533339A (en) * 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
PT1735348E (pt) * 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her

Also Published As

Publication number Publication date
CA2373815A1 (fr) 2000-11-23
CZ20014083A3 (cs) 2002-08-14
PL365999A1 (en) 2005-01-24
AU782994B2 (en) 2005-09-15
BR0010524A (pt) 2002-05-28
EP1218032A1 (fr) 2002-07-03
CN1200734C (zh) 2005-05-11
EP2042194A2 (fr) 2009-04-01
US20020012663A1 (en) 2002-01-31
BG106110A (bg) 2002-04-30
NO20015546D0 (no) 2001-11-13
EE200100603A (et) 2003-02-17
MXPA01011632A (es) 2002-11-07
HUP0201480A3 (en) 2009-03-30
JP2009120583A (ja) 2009-06-04
HK1047236A1 (zh) 2003-02-14
KR20020000223A (ko) 2002-01-05
US20050112120A1 (en) 2005-05-26
HUP0201480A2 (en) 2002-08-28
WO2000069459A1 (fr) 2000-11-23
JP2003520195A (ja) 2003-07-02
IL146480A0 (en) 2002-07-25
AU4687100A (en) 2000-12-05
US20030157104A1 (en) 2003-08-21
EP1218032A4 (fr) 2005-05-25
CN1361700A (zh) 2002-07-31
EP2042194A3 (fr) 2009-04-22
RU2294761C2 (ru) 2007-03-10
SK16522001A3 (sk) 2002-10-08
AU782994C (en) 2006-08-24

Similar Documents

Publication Publication Date Title
NO20015546D0 (no) Behandling av refrakt¶re humane tumorer med epidermale vekstfaktorreseptorantagonister
NO20030603L (no) Behandling av hyperprolifererende sykdommer med epidermal vekstfaktorreseptorantagonister
EP1080113A4 (fr) Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance
EE200200673A (et) Kinasoliini derivaadid kasvajate raviks
ATE399541T1 (de) Epidermale wachstumsfaktor rezeptor antagonisten zur behandlung stark vermehrter schleimsekretion in der lunge
EE200200118A (et) Terapeutilised kinasoliini derivaadid, nende valmistamise meetod ning kasutamine
ITMI991608A0 (it) Sonda elettrochirurgica per il trattamento di tumori mediante radiofre quenza
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
DE60033030D1 (de) Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit
ATE231869T1 (de) Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung
PL353854A1 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
NO20012367D0 (no) Behandling av tumorer ved administrering av veksthormonfrigjörende forbindelser og deres antagonister
EP1401431A4 (fr) Antagonistes de l'hormone de croissance humaine
ATE265862T1 (de) Programmierte ovarielle stimulationsbehandlungprotokoll unter verwendung von oralen kontrazeptiva
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DK1165071T3 (da) Forbedret cancerbehandling med temozolomid
DE69933057D1 (de) Analoge des humanen basischen fibroblasten-wachstumsfactors
NO20021430L (no) Fremgangsmåte for terapeutisk forvaltning av ekstrauterin proliferering av endometrievev, kronisk bekkensmerte ogegglederobstruksjon
DE60002043D1 (de) 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b]indol-1-carboxamid-derivate, ihre herstellung und therapeutische verwendung
IL151992A0 (en) Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
DE60112423D1 (de) Verwendung von substituierten distamycin-acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen
ZA200109347B (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists.
ATE261965T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
DE60035991D1 (de) 1,4-dithiin und 1,4-dithiepin-1,1,4,4, tetroxid derivate verwendbar als human galanin receptor antagonisten
ATE259809T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application